Rapamycin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Rapamycin is an approved drug that blocks mTOR, a growth switch in cells. It makes many kinds of animals live longer. Some people take low, spaced-out doses for ageing, off-label. Studies in people are small.
Evidence grade for Rapamycin: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 2 completed trials, 25 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 25
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved (Rapamune); use for longevity is off-label (not what it is approved for) and investigational
8 effects reported, 5 unwanted, 3 wanted, by people using it, not a trial
Goal pages: Muscle and strength, Ageing and longevity
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Rapamycin is a prescription drug that turns down a growth switch inside your cells. It is approved to stop the body rejecting a transplant. It is the best drug there is at making mice live longer. Some people take a low dose once a week to try to get that in humans. That use is not approved.
What people take it for
- Living longer.
- Staying healthy for more of their life.
- A stronger immune response as they age.
- Getting the benefits of fasting without fasting.
What studies in people showed
People first. Nobody has tested whether rapamycin makes a person live longer. The PEARL trial gave a low weekly dose for 48 weeks to healthy ageing adults. It was fairly safe. Women on 10 mg gained some lean mass and had less pain. That is one year and one small trial. It is not a lifespan result. In 2014, a cousin of this drug at a low dose helped older adults respond better to a flu shot. That was the first human sign of anything. Now mice, which is why people care. In 2009, old mice got rapamycin starting at 600 days of age. Females lived 14 percent longer and males 9 percent longer, counting the longest lived mice. It worked at three separate labs.
What people report
Reports, not study results
The good
- People say they feel better and have more energy. Users who stay on it rate their own health higher.
- Some say they get fewer colds.
- Less joint pain, which matches the women in PEARL.
The bad
- Mouth sores. This is the most common complaint, and the only side effect a user survey found more often than in non-users.
- Higher triglycerides and LDL on blood work. Doctors who prescribe it check lipids every few months for this reason.
- Infections and slow wound healing, more so at higher doses. It is an immune drug and this is what immune drugs do.
- Higher blood sugar in some people.
- Stomach upset. PEARL saw more of this on the drug than on the dummy pill.
Where these come from: The PEARL side effect tables, a published survey of off-label users, and the drug's own label for transplant doses. The feel-better and fewer-colds reports are from longevity forums and clinic write-ups. Those are self-report.
My bottom line
This is the real thing in mice and an open question in people. It is a prescription immune drug with mouth sores and lipid changes on the record. If you take it, you take it with a doctor and blood work, not a vial from the internet.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Rapamycin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Living longer25 people · 1 study
- Keeping or building muscleno headcount stated · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Rapamycin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
28 of the 36 indexed goals have no study of any kind behind Rapamycin
No study in people, animals or cells on this page reports a result for these. That does not prove Rapamycin does nothing for them. It does mean anything you have heard about Rapamycin and one of these did not come from a study cited here.
Show full evidence
What is Rapamycin?
Rapamycin is an approved drug that blocks mTOR, a growth switch in cells. It makes many kinds of animals live longer. Some people take low, spaced-out doses for ageing, off-label. Studies in people are small.
Rapamycin, also called sirolimus, is an approved drug. It stops the body rejecting a transplant and treats some other conditions. It blocks mTOR, a main switch that tells cells to grow when food is around. In the PEARL study, 48 weeks of low doses taken now and then were fairly safe in ordinary ageing adults. Women on 10 mg gained lean mass and had less pain. In a small study of 25 people aged 70 to 95, 1 mg a day was safe enough to keep going. No study has tested whether it helps people live longer. In animals, it is one of the most reliable ways to extend life, across many species. That is why people are interested in low doses for healthy ageing. Using it for ageing is off-label and experimental.
How does Rapamycin work?
It blocks the mTOR pathway. That copies part of what eating less does to cells, and it boosts cell clean-up and upkeep.
What have studies in people found about Rapamycin?
Two small studies of rapamycin itself in older adults, plus a flu shot study of a related drug. The mouse lifespan results are the strongest animal results on this site. The results in people are far behind.
- PEARL: 48 weeks of low doses taken now and then, in ordinary ageing adults. The main question was safety, and the answer was fairly reassuring. Women on 10 mg gained lean mass and had less pain. That was one result among many and needs repeating.
- Kraig 2018: 25 adults aged 70 to 95 took 1 mg a day or a dummy pill. 11 on rapamycin and 14 on the dummy finished at least 8 weeks. It checked whether people could take it, not whether it worked.
- Mannick 2014 used everolimus, a related drug, not rapamycin. It measured the response to a flu shot, not illness prevented or life extended. It is marked on its card and not counted here.
- No study has tested whether rapamycin helps people live longer.
What this does not tell you: Everything in people here is short and small, and aimed at safety or a stand-in marker. The mouse result is strong, and it is a mouse result. Transplant studies use a different dose, a different goal and different patients, so they are not added here to pad the file.
What do people who took Rapamycin report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Everything described is weekly or less often rather than daily. Reported amounts run from about 1.25 mg to 15 mg weekly, with most clustering in the low single digits, and some people moving to a larger amount every two weeks instead. The schedules are self-designed and posters say so.
- The most distinctive single report is joint pain changing within hours of a dose and staying changed for much of the week. Other reports cover body weight, memory and work performance, and shifts in routine bloodwork. Attribution is loose throughout, because almost everyone posting is running several other things at the same time.
- Mouth sores and rashes are the most consistently described problem, and people describe them settling when they pause or lower the dose. Raised blood glucose is discussed as an expected consequence rather than a surprise, insomnia is described after the first doses, and worry about lowered white blood cells and infection risk recurs without an answer.
- Reports of nothing happening are present and are not treated as unusual. One recurring shape is someone running it for a couple of months, seeing no change in the thing they started for, and reporting one narrow unrelated change instead.
- Product identity is a live argument. People distinguish branded sirolimus from cheap generics and from bulk powder, and a failed run is routinely blamed on the product rather than the compound. Some describe confirming a source by blood level testing, which is the only verification step that appears.
- People describe checking blood fats, blood sugar, kidney markers and white blood cell counts, and results are reported as going in different directions between individuals. The people posting are those who chose to take a prescription drug that dampens the immune system without a medical reason for it, which is worth holding in mind when reading their conclusions.
Sources: Rapamycin experience and dosing threads on LongeCity, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
The evidence, in charts
Fig. 1a · how many people
25people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Experimental Gerontology 2018 | 25 | 100% |
The whole total is one study of 25. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 sources here are studies in people. The rest is not.
- Study in people · done in people375%
- Animal study · done in animals125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2009 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 914.2 Da
- Half-life
- About 2.5 daysLong, 1 to 7 days
- Chain length
- None on file
No amino acid sequence is on file for Rapamycin, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2014mTOR inhibition improves immune function in the elderly
Older adults given a low dose of a cousin of this drug responded better to their flu vaccine. The drug in that trial was everolimus, not rapamycin. What was measured was the immune response to a vaccine. Not illness prevented, not life extended. It is the study that started this whole field, and it is not a trial of the molecule on this page.
Low-dose mTOR inhibitor (everolimus) enhanced influenza vaccine response in older adults, the first human aging-related signal. Counted as a cousin-molecule result, not as rapamycin.
This study gave people everolimus, not Rapamycin. It is here because it belongs on the record, and it is excluded from every count on this page.
- Study in people2025Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Nearly a year of low dose rapamycin proved reasonably safe in ordinary ageing adults. Safety was the main thing the trial was built to check, and it checked out. Muscle mass and pain improved in women on the higher dose, which was one finding among many measures and needs repeating before anyone leans on it. Safe to take is not the same as doing something.
48 weeks of low-dose intermittent rapamycin was relatively safe in normative-aging adults; lean mass and pain improved in women on 10 mg.
- Study in people2018A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects
The first safety look at rapamycin itself in fairly healthy older adults was small. 25 people aged 70 to 95 took 1 mg a day or a dummy pill. 11 on rapamycin and 14 on the dummy finished at least 8 weeks. The study was built to see if they could take it, not to see if they aged slower. Face rash and mouth sores showed up. Do not read a lifespan claim into it.
Placebo-controlled pilot in 25 generally healthy adults aged 70 to 95, randomised to rapamycin 1 mg daily or placebo. 11 on rapamycin and 14 controls completed at least 8 weeks and were analysed. The trial found the dose was safe enough to continue. It did not test lifespan.
- Animal study2009Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
In mice: started at 600 days old, which is late in life, rapamycin made mice live longer at three separate labs. Among the longest lived, females gained 14 percent and males 9 percent.
Started at 600 days of age, rapamycin extended lifespan at three sites: 14% in females and 9% in males at the 90th percentile.
Common questions
Has Rapamycin been tested in people?
Yes. 25 people given it across 2 completed trials cited here, 0 of which found nothing. Rapamycin is an approved drug that blocks mTOR, a growth switch in cells. It makes many kinds of animals live longer. Some people take low, spaced-out doses for ageing, off-label. Studies in people are small.
What is the Rapamycin dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved (Rapamune); use for longevity is off-label (not what it is approved for) and investigational
Is Rapamycin FDA-approved?
FDA-approved (Rapamune); use for longevity is off-label (not what it is approved for) and investigational
Do people take rapamycin for longevity?
Some do. They take low doses now and then, off-label, with a doctor watching, because the animal results are strong. It is not proven to help people live longer. It is a prescription drug that turns down the immune system, and it has real risks.
Latest reading on Rapamycin
Blog posts about Rapamycin, newest first.
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 27, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 27, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven